中医药治疗风湿免疫领域临床优势病种的探讨  

Expert Consensus on Rheumatic Immune Diseases Responding Specifically to Traditional Chinese Medicine

作　　者：徐愿[1] 罗静[1] 韩曼[2] 李梦涛[3] 侯秀娟[4] 吴迪[3] 李斌[5] 耿研[6] 周云杉[7] 李常虹[8] 李坤鹏[9] 王伽伯 王勇 张霄潇[12] 陶庆文[1] XU Yuan;LUO Jing;HAN Man;LI Meng-tao;HOU Xiu-juan;WU Di;LI Bin;GENG Yan;ZHOU Yun-shan;LI Chang-hong;LI Kun-peng;WANG Jia-bo;WANG Yong;ZHANG Xiao-xiao;TAO Qing-wen(China-Japan Friendship Hospital,Beijing 100029,China;Guanganmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;Peking Union Medical College Hospital,China Academy of Medical Sciences,Beijing 100730,China;Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China;Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Peking University First Hospital,Beijing 100034,China;Peking University People's Hospital,Beijing 100044,China;Peking University Third Hospital,Beijing 100191,China;Chinese People's Liberation Army General Hospital,Beijing 100039,China;School of Chinese Medicine,Capital Medical University,Beijing 100013,China;School of Traditional Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100029,China;China Association of Chinese Medicine,Beijing 100029,China)

机构地区：[1]中日友好医院,北京100029 [2]中国中医科学院广安门医院,北京100053 [3]中国医学科学院北京协和医院,北京100730 [4]北京中医药大学东方医院,北京100078 [5]中国中医科学院西苑医院,北京100091 [6]北京大学第一医院,北京100034 [7]北京大学人民医院,北京100044 [8]北京大学第三医院,北京100191 [9]中国人民解放军总医院,北京100039 [10]首都医科大学中医药学院,北京100013 [11]北京中医药大学中医学院,北京100029 [12]中华中医药学会,北京100029

出　　处：《中国实验方剂学杂志》2022年第9期198-204,共7页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：北京市中医药科技发展资金项目(QN-2020-32);北京中医药大学教育课题(XJYB1963);国家重点研发计划项目(2018YFC1705502)。

摘　　要：中医药治疗风湿免疫疾病的优势病种、中西医结合切入点仍不明确,制订中医、西医普遍认可、融合的诊疗方案是亟待解决的问题。为明确中医、中西医结合风湿病优势病种和优势环节,由中华中医药学会发起风湿领域中医优势病种青年沙龙研讨会(以下简称风湿优势病种青年沙龙),以广泛涵盖中医、西医风湿领域专家的研讨小组为主体,采用问卷调查和现场研讨两种形式,充分探讨中医药治疗风湿免疫疾病的优势,明确中西医结合切入点,初步形成一致意见,为制订出中医西医普遍认可、融合的诊疗方案提供基础。风湿优势病种青年沙龙与会专家一致认为,应结合现代医学方法、现代科技手段开展循证医学研究,为践行“宜中则中、宜西则西”的指导思想提供客观临床证据;要以“四个互”为要求,即语境互通、学理互释、标准互证、手段互融,要着重解决难治性风湿病;在优势病种和优势点上,本文介绍达成广泛共识的类风湿关节炎、强直性脊柱炎、干燥综合征、高尿酸血症与痛风、系统性红斑狼疮、纤维肌痛综合征等6种优势疾病的21个优势环节。本研究为风湿病中医、中西医结合诊疗方案提供参考,为临床实际诊疗和科学研究提供参考依据和有益借鉴。In the clinical practice of rheumatic immune diseases in traditional Chinese medicine(TCM),it`s still unclear about the dominant diseases and breakthrough points.It`s urgent missions to formulate TCM diagnosis and treatment guidelines widely recognized and integrated by traditional Chinese medicine and Western medicine.In order to clarify the dominant diseases and breakthrough points in rheumatism,China association of Chinese medicine initiated a research group covering experts in the field of rheumatism of traditional Chinese medicine and Western medicine.Based on questionnaire survey and on-site discussion,experts had reached the following consensus.Evidence-based medicine research using modern medical methods and scientific methods should be carried out to provide objective clinical evidences."Four mutuality"were put forward as the basis for the work of integrated traditional Chinese and Western medicine,that is the mutual communication using the exchangeable context,the mutual explanation using common theories,the mutual certification using common standards,and the mutual integration using common means.Key works should focus on solving refractory rheumatism in the future.In terms of dominant diseases and breakthrough points,this paper introduces21 breakthrough points in 6 dominant diseases,including rheumatoid arthritis,ankylosing spondylitis,Sjogren’s syndrome,hyperuricemia and gout,systemic lupus erythematosus and fibromyalgia syndrome.Advice on this discussion can provide valuable references for developing the treatment scheme of rheumatism with TCM and integrated Chinese and Western medicine and clinical practice and scientific research.

关 键 词：风湿免疫科 优势病种 中西医结合 专家指导建议 

分 类 号：R242[医药卫生—中医临床基础] R2-0[医药卫生—中医学]